Genocea Biosciences Inc.'s latest, 12-month, dose-optimization phase II results with its GEN-003 vaccine immunotherapy for genital herpes compare well with those achieved by way of currently available, daily, oral medicine, and a phase IIb efficacy trial with the injectable alternative goes on.